Narrowband UVB remains first-line phototherapy for vitiligo, with JAK inhibitors emerging as adjuncts
New light therapies and skin grafts offer hope for vitiligo patients
This narrative review synthesizes current evidence on phototherapy for vitiligo, highlighting narrowband UVB as the mainstay. Excimer lasers…
A review of treatments for vitiligo highlights options like narrowband ultraviolet B light, excimer therapy, and cellular grafting that may …
Commentary on plateau in lupus nephritis trials and path to precision medicine
New lupus drugs hit a ceiling where kidney healing stops improving
This commentary reviews 200 interventional pharmacological trials in lupus nephritis. The authors note a persistent ceiling effect with comp…
Kidney healing in lupus patients using new drugs often stops improving after reaching a 40 to 50 percent success rate, limiting how much bet…
Review synthesizes Treg biology and NB-UVB, JAK inhibitors, IL-2 in vitiligo patients
Review shows immune cells may be off in vitiligo
This narrative review examines Treg biology and immunoregulatory functions alongside NB-UVB, JAK inhibitors, and low-dose IL-2 in vitiligo p…
A review finds immune cells that calm inflammation are fewer and less effective in people with vitiligo, suggesting a path for future treatm…
Clinical features and treatment responses in 40 male patients with VEXAS syndrome
HMA treatment shows promise for VEXAS syndrome patients
This retrospective multicenter study of 40 male patients with VEXAS syndrome evaluated clinical features and various treatment responses.
New data on VEXAS syndrome suggests that hypomethylating agents may help improve clinical and biological responses in men.
Guselkumab showed improved clinical remission in refractory ulcerative colitis versus placebo
Guselkumab shows promise for ulcerative colitis in this early phase 3 trial
This phase 3 randomized trial evaluated guselkumab in adults with moderately to severely active ulcerative colitis who had inadequate respon…
Patients with ulcerative colitis who failed other treatments achieved remission in a new trial using subcutaneous guselkumab injections.